Preoperative bevacizumab Fulvestrant in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer. Ann Thorac Surg 2011; 91: 640PubMedCrossRef 13. Fischbach NA, Spigel D, Brahmer J, et al. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: a bevacizumab (BV) treatment observational cohort study (OCS) [abstract]. J Clin Oncol 2009; 27(15s): abstract no. 8040 [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30542
[Accessed 2012 Nov 14] 14. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed
in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543–51PubMedCrossRef 15. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance Entinostat nmr pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27: 3284–9PubMedCrossRef 16. Ciuleanu T, https://www.selleckchem.com/products/GSK1904529A.html Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432–40PubMedCrossRef 17. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521–9PubMedCrossRef 18. Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab PLEK2 in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460–8PubMedCrossRef 19. Schutz FA, Je Y, Azzi GR, et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.
Ann Oncol 2011; 22: 1404–12PubMedCrossRef 20. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277–85PubMedCrossRef 21. Schutz FA, Jardim DL, Je Y, et al. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer 2011; 47: 1161–74PubMedCrossRef 22. European Medicines Agency Committee for Medicinal Products for Human Use. Post-authorisation summary of positive opinion for Avastin [online]. Available from URL: http://www.emea.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000582/WC500059419.pdf [Accessed 2012 Nov 20] 23. Mok TS, Hsia TC, Tsai CM, et al.